{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T18:46:18Z","timestamp":1790880378813,"version":"4.1.0"},"reference-count":74,"publisher":"Bentham Science Publishers Ltd.","issue":"1","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CN"],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background::<\/jats:title>\n                    <jats:p>In the current management of neuropathic pain, in addition to antidepressants\nand anticonvulsants, the use of opioids is wide, despite their related and well-known issues.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective::<\/jats:title>\n                    <jats:p>N-palmitoylethanolamine (PEA), a natural fatty-acid ethanolamide whose anti-inflammatory,\nneuroprotective, immune-modulating and anti-hyperalgesic activities are known, represents a promising\ncandidate to modulate and\/or potentiate the action of opioids.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods::<\/jats:title>\n                    <jats:p>This study was designed to evaluate if the preemptive and morphine concomitant administration\nof ultramicronized PEA, according to fixed or increasing doses of both compounds, delays\nthe onset of morphine tolerance and improves its analgesic efficacy in the chronic constriction injury\n(CCI) model of neuropathic pain in rats.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results::<\/jats:title>\n                    <jats:p>Behavioral experiments showed that the preemptive and co-administration of ultramicronized\nPEA significantly decreased the effective dose of morphine and delayed the onset of morphine tolerance.\nThe activation of spinal microglia and astrocytes, commonly occurring both on opioid treatment and neuropathic\npain, was investigated through GFAP and Iba-1 immunofluorescence. Both biomarkers were\nfound to be increased in CCI untreated or morphine treated animals in a PEA-sensitive manner. The increased\ndensity of endoneural mast cells within the sciatic nerve of morphine-treated and untreated CCI\nrats was significantly reduced by ultramicronized PEA. The decrease of mast cell degranulation, evaluated\nin terms of reduced plasma levels of histamine and N-methyl-histamine metabolite, was mainly\nobserved at intermediate-high doses of ultramicronized PEA, with or without morphine.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion::<\/jats:title>\n                    <jats:p>Overall, these results show that the administration of ultramicronized PEA in CCI rats\naccording to the study design fully fulfilled the hypotheses of this study.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/1570159x21666221128091453","type":"journal-article","created":{"date-parts":[[2022,11,29]],"date-time":"2022-11-29T00:53:42Z","timestamp":1669683222000},"page":"88-106","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Ultramicronized N-palmitoylethanolamine Contributes to Morphine\nEfficacy Against Neuropathic Pain: Implication of Mast Cells and Glia"],"prefix":"10.2174","volume":"22","author":[{"given":"Laura","family":"Micheli","sequence":"first","affiliation":[{"name":"Department of Neuroscience, Psychology, Drug Research and Child Health - NEUROFARBA - Pharmacology and\nToxicology Section, University of Florence, Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Lucarini","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, Psychology, Drug Research and Child Health - NEUROFARBA - Pharmacology and\nToxicology Section, University of Florence, Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Nobili","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, Psychology, Drug Research and Child Health - NEUROFARBA - Pharmacology and\nToxicology Section, University of Florence, Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Bartolucci","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, Psychology, Drug Research\nand Child Health - NEUROFARBA - Pharmaceutical and Nutraceutical Sciences Section, University of Florence,\nFlorence, 50019, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Pallecchi","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, Psychology, Drug Research\nand Child Health - NEUROFARBA - Pharmaceutical and Nutraceutical Sciences Section, University of Florence,\nFlorence, 50019, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Toti","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, Psychology, Drug Research and Child Health - NEUROFARBA - Pharmacology and\nToxicology Section, University of Florence, Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Ferrara","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, Psychology, Drug Research and Child Health - NEUROFARBA - Pharmacology and\nToxicology Section, University of Florence, Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Ciampi","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, Psychology, Drug Research and Child Health - NEUROFARBA - Pharmacology and\nToxicology Section, University of Florence, Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Ghelardini","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, Psychology, Drug Research and Child Health - NEUROFARBA - Pharmacology and\nToxicology Section, University of Florence, Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Di Cesare Mannelli","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, Psychology, Drug Research and Child Health - NEUROFARBA - Pharmacology and\nToxicology Section, University of Florence, Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1212\/01.wnl.0000282763.29778.59","volume":"70","author":"Treede R.D.","year":"2008","unstructured":"Treede R.D.; Jensen T.S.; Campbell J.N.; Cruccu G.; Dostrovsky J.O.; Griffin J.W.; Hansson P.; Hughes R.; Nurmikko T.; Serra J.; Neuropathic pain: Redefinition and a grading system for clinical and research purposes. Neurology 2008,70(18),1630-1635","journal-title":"Neurology"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"17002","DOI":"10.1038\/nrdp.2017.2","volume":"3","author":"Colloca L.","year":"2017","unstructured":"Colloca L.; Ludman T.; Bouhassira D.; Baron R.; Dickenson A.H.; Yarnitsky D.; Freeman R.; Truini A.; Attal N.; Finnerup N.B.; Eccleston C.; Kalso E.; Bennett D.L.; Dworkin R.H.; Raja S.N.; Neuropathic pain. Nat Rev Dis Primers 2017,3(1),17002","journal-title":"Nat Rev Dis Primers"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"S127","DOI":"10.1097\/j.pain.0000000000001824","volume":"161","author":"Smith B.H.","year":"2020","unstructured":"Smith B.H.; H\u00e9bert H.L.; Veluchamy A.; Neuropathic pain in the community: Prevalence, impact, and risk factors. Pain 2020,161(Suppl. 1),S127-S137","journal-title":"Pain"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1474-4422(14)70251-0","volume":"14","author":"Finnerup N.B.","year":"2015","unstructured":"Finnerup N.B.; Attal N.; Haroutounian S.; McNicol E.; Baron R.; Dworkin R.H.; Gilron I.; Haanp\u00e4 M.; Hansson P.; Jensen T.S.; Kamerman P.R.; Lund K.; Moore A.; Raja S.N.; Rice A.S.C.; Rowbotham M.; Sena E.; Siddall P.; Smith B.H.; Wallace M.; Pharmacotherapy for neuropathic pain in adults: A systematic review and meta-analysis. Lancet Neurol 2015,14(2),162-173","journal-title":"Lancet Neurol"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"3533","DOI":"10.3390\/jcm10163533","volume":"10","author":"Serrano A.","year":"2021","unstructured":"Serrano A.; Carnaval T.; Videla C\u00e9s S.; Combination therapy for neuropathic pain: A review of recent evidence. J Clin Med 2021,10(16),3533","journal-title":"J Clin Med"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.coms.2021.09.002","volume":"34","author":"Nudell Y.","year":"2022","unstructured":"Nudell Y.; Dym H.; Sun F.; Benichou M.; Malakan J.; Halpern L.R.; Pharmacologic management of neuropathic pain. Oral Maxillofac Surg Clin North Am 2022,34(1),61-81","journal-title":"Oral Maxillofac Surg Clin North Am"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/ejp.1494","volume":"24","author":"Sommer C.","year":"2020","unstructured":"Sommer C.; Klose P.; Welsch P.; Petzke F.; H\u00e4user W.; Opioids for chronic non\u2010cancer neuropathic pain. An updated systematic review and meta\u2010analysis of efficacy, tolerability and safety in randomized placebo\u2010controlled studies of at least 4 weeks duration. Eur J Pain 2020,24(1),3-18","journal-title":"Eur J Pain"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"5577","DOI":"10.1021\/ja01577a066","volume":"79","author":"Kuehl F.A.","year":"1957","unstructured":"Kuehl F.A.; Jacob T.A.; Ganley O.H.; Ormond R.E.; Meisinger M.A.P.; The identification of N-(2-hydroxyethyl)-palmitoile as a naturally occuring anti-inflammatory agent. J Am Chem Soc 1957,79(20),5577-5578","journal-title":"J Am Chem Soc"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"C145","DOI":"10.1007\/BF01972748","volume":"39","author":"Aloe L.","year":"1993","unstructured":"Aloe L.; Leon A.; Levi-Montalcini R.; A proposed autacoid mechanism controlling mastocyte behaviour. Agents Actions 1993,39(S1),C145-C147","journal-title":"Agents Actions"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2015\/894732","volume":"2015","author":"Di Cesare Mannelli L.","year":"2015","unstructured":"Di Cesare Mannelli L.; Corti F.; Micheli L.; Zanardelli M.; Ghelardini C.; Delay of morphine tolerance by palmitoylethanolamide. BioMed Res Int 2015,2015,1-12","journal-title":"BioMed Res Int"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2013\/328797","volume":"2013","author":"Di Cesare Mannelli L.","year":"2013","unstructured":"Di Cesare Mannelli L.; D\u2019Agostino G.; Pacini A.; Russo R.; Zanardelli M.; Ghelardini C.; Calignano A.; Palmitoylethanolamide is a disease-modifying agent in peripheral neuropathy: pain relief and neuroprotection share a PPAR-alpha-mediated mechanism. Mediators Inflamm 2013,2013,1-12","journal-title":"Mediators Inflamm"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"e0128080","DOI":"10.1371\/journal.pone.0128080","volume":"10","author":"Di Cesare Mannelli L.","year":"2015","unstructured":"Di Cesare Mannelli L.; Pacini A.; Corti F.; Boccella S.; Luongo L.; Esposito E.; Cuzzocrea S.; Maione S.; Calignano A.; Ghelardini C.; Antineuropathic profile of N-palmitoylethanolamine in a rat model of oxaliplatin-induced neurotoxicity. PLoS One 2015,10(6),e0128080","journal-title":"PLoS One"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"473","DOI":"10.3389\/fphar.2018.00473","volume":"9","author":"Di Cesare Mannelli L.","year":"2018","unstructured":"Di Cesare Mannelli L.; Micheli L.; Lucarini E.; Ghelardini C.; Ultramicronized N-palmitoylethanolamine supplementation for long-lasting, low-dosed morphine antinociception. Front Pharmacol 2018,9,473","journal-title":"Front Pharmacol"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1007\/s12035-015-9253-8","volume":"52","author":"Skaper S.D.","year":"2015","unstructured":"Skaper S.D.; Facci L.; Barbierato M.; Zusso M.; Bruschetta G.; Impellizzeri D.; Cuzzocrea S.; Giusti P.; N-palmitoylethanolamine and neuroinflammation: A novel therapeutic strategy of resolution. Mol Neurobiol 2015,52(2),1034-1042","journal-title":"Mol Neurobiol"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"3509","DOI":"10.3390\/ijms21103509","volume":"21","author":"Peritore A.F.","year":"2020","unstructured":"Peritore A.F.; Siracusa R.; Fusco R.; Gugliandolo E.; D\u2019Amico R.; Cordaro M.; Crupi R.; Genovese T.; Impellizzeri D.; Cuzzocrea S.; Di Paola R.; Ultramicronized palmitoylethanolamide and paracetamol, a new association to relieve hyperalgesia and pain in a sciatic nerve injury model in rat. Int J Mol Sci 2020,21(10),3509","journal-title":"Int J Mol Sci"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"5305","DOI":"10.3390\/ijms22105305","volume":"22","author":"Clayton P.","year":"2021","unstructured":"Clayton P.; Hill M.; Bogoda N.; Subah S.; Venkatesh R.; Palmitoylethanolamide: A natural compound for health management. Int J Mol Sci 2021,22(10),5305","journal-title":"Int J Mol Sci"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.3390\/ijms22041967","volume":"22","author":"Ardizzone A.","year":"2021","unstructured":"Ardizzone A.; Fusco R.; Casili G.; Lanza M.; Impellizzeri D.; Esposito E.; Cuzzocrea S.; Effect of ultra-micronized-palmitoylethanolamide and acetyl-l-carnitine on experimental model of inflammatory pain. Int J Mol Sci 2021,22(4),1967","journal-title":"Int J Mol Sci"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.neuropharm.2006.08.011","volume":"52","author":"Petrosino S.","year":"2007","unstructured":"Petrosino S.; Palazzo E.; de Novellis V.; Bisogno T.; Rossi F.; Maione S.; Di Marzo V.; Changes in spinal and supraspinal endocannabinoid levels in neuropathic rats. Neuropharmacology 2007,52(2),415-422","journal-title":"Neuropharmacology"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"2722","DOI":"10.1007\/s13311-021-01116-4","volume":"18","author":"Congiu M.","year":"2021","unstructured":"Congiu M.; Micheli L.; Santoni M.; Sagheddu C.; Muntoni A.L.; Makriyannis A.; Malamas M.S.; Ghelardini C.; Di Cesare Mannelli L.; Pistis M.; N-Acylethanolamine acid amidase inhibition potentiates morphine analgesia and delays the development of tolerance. Neurotherapeutics 2021,18(4),2722-2736","journal-title":"Neurotherapeutics"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"3189","DOI":"10.1111\/bph.12955","volume":"172","author":"McGrath J.C.","year":"2015","unstructured":"McGrath J.C.; Lilley E.; Implementing guidelines on reporting research using animals (ARRIVE etc.): New requirements for publication in BJP. Br J Pharmacol 2015,172(13),3189-3193","journal-title":"Br J Pharmacol"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/0304-3959(88)90209-6","volume":"33","author":"Bennett G.J.","year":"1988","unstructured":"Bennett G.J.; Xie Y.K.; A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man. Pain 1988,33(1),87-107","journal-title":"Pain"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1111\/j.1476-5381.1988.tb10310.x","volume":"93","author":"Leighton G.E.","year":"1988","unstructured":"Leighton G.E.; Rodriguez, R.E.; Hill, R.G.; Hughes, J. \u03ba-Opioid agonists produce antinociception after i.v. and i.c.v. but not intrathecal administration in the rat. Br J Pharmacol 1988,93(3),553-560","journal-title":"Br J Pharmacol"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1016\/j.jpain.2013.08.002","volume":"14","author":"Di Cesare Mannelli L.","year":"2013","unstructured":"Di Cesare Mannelli L.; Pacini A.; Bonaccini L.; Zanardelli M.; Mello T.; Ghelardini C.; Morphologic features and glial activation in rat oxaliplatin-dependent neuropathic pain. J Pain 2013,14(12),1585-1600","journal-title":"J Pain"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1007\/s00280-017-3449-8","volume":"80","author":"Di Cesare Mannelli L.","year":"2017","unstructured":"Di Cesare Mannelli L.; Maresca M.; Micheli L.; Farina C.; Scherz M.W.; Ghelardini C.; A rat model of FOLFOX-induced neuropathy: Effects of oral dimiracetam in comparison with duloxetine and pregabalin. Cancer Chemother Pharmacol 2017,80(6),1091-1103","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1186\/1471-2474-14-228","volume":"14","author":"Di C.M.L.","year":"2013","unstructured":"Di C.M.L.; Micheli L.; Zanardelli M.; Ghelardini C.; Low dose native type II collagen prevents pain in a rat osteoarthritis model. BMC Musculoskelet Disord 2013,14(1),228","journal-title":"BMC Musculoskelet Disord"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1111\/jphp.12828","volume":"69","author":"Maresca M.","year":"2017","unstructured":"Maresca M.; Micheli L.; Cinci L.; Bilia A.R.; Ghelardini C.; Di C.M.L.; Pain relieving and protective effects of Astragalus hydroalcoholic extract in rat arthritis models. J Pharm Pharmacol 2017,69(12),1858-1870","journal-title":"J Pharm Pharmacol"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0169-328X(98)00040-0","volume":"57","author":"Ito D.","year":"1998","unstructured":"Ito D.; Imai Y.; Ohsawa K.; Nakajima K.; Fukuuchi Y.; Kohsaka S.; Microglia-specific localisation of a novel calcium binding protein, Iba1. Brain Res Mol Brain Res 1998,57(1),1-9","journal-title":"Brain Res Mol Brain Res"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1071\/FP18316","volume":"46","author":"Ben Saad R.","year":"2019","unstructured":"Ben Saad R.; Harbaoui M.; Ben Romdhane W.; Zouari N.; Giang K.N.; Ben Hsouna A.; Brini F.; Overexpression of triticum durum TdAnn12 gene confers stress tolerance through scavenging reactive oxygen species in transgenic tobacco. Funct Plant Biol 2019,46(10),885-895","journal-title":"Funct Plant Biol"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"403","DOI":"10.3390\/pharmaceutics14020403","volume":"14","author":"Micheli L.","year":"2022","unstructured":"Micheli L.; Lucarini E.; Toti A.; Ferrara V.; Ciampi C.; Parisio C.; Bartolucci G.; Di Cesare Mannelli L.; Ghelardini C.; Effects of ultramicronized N-palmitoylethanolamine supplementation on tramadol and oxycodone analgesia and tolerance prevention. Pharmaceutics 2022,14(2),403","journal-title":"Pharmaceutics"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1111\/j.1526-4637.2009.00588.x","volume":"10","author":"Yawn B.P.","year":"2009","unstructured":"Yawn B.P.; Wollan P.C.; Weingarten T.N.; Watson J.C.; Hooten W.M.; Melton L.J.; The prevalence of neuropathic pain: Clinical evaluation compared with screening tools in a community population. Pain Med 2009,10(3),586-593","journal-title":"Pain Med"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"2525","DOI":"10.2147\/JPR.S127014","volume":"10","author":"DiBonaventura M.","year":"2017","unstructured":"DiBonaventura M.; Sadosky A.; Concialdi K.; Hopps M.; Kudel I.; Parsons B.; Cappelleri J.C.; Hlavacek P.; Alexander A.; Stacey B.R.; Markman J.D.; Farrar J.T.; The prevalence of probable neuropathic pain in the US: Results from a multimodal general-population health survey. J Pain Res 2017,10,2525-2538","journal-title":"J Pain Res"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"5330","DOI":"10.3390\/ijms21155330","volume":"21","author":"D\u2019Amico R.","year":"2020","unstructured":"D\u2019Amico R.; Impellizzeri D.; Cuzzocrea S.; Di Paola R.; Aliamides update: Palmitoylethanolamide and its formulations on management of peripheral neuropathic pain. Int J Mol Sci 2020,21(15),5330","journal-title":"Int J Mol Sci"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"3604","DOI":"10.3390\/ijms22073604","volume":"22","author":"Alessio N.","year":"2021","unstructured":"Alessio N.; Belardo C.; Trotta M.C.; Paino S.; Boccella S.; Gargano F.; Pieretti G.; Ricciardi F.; Marabese I.; Luongo L.; Galderisi U.; D\u2019Amico M.; Maione S.; Guida F.; Vitamin D deficiency induces chronic pain and microglial phenotypic changes in mice. Int J Mol Sci 2021,22(7),3604","journal-title":"Int J Mol Sci"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"3054","DOI":"10.3390\/ijms22063054","volume":"22","author":"D\u2019Aloia A.","year":"2021","unstructured":"D\u2019Aloia A.; Molteni L.; Gullo F.; Bresciani E.; Artusa V.; Rizzi L.; Ceriani M.; Meanti R.; Lecchi M.; Coco S.; Costa B.; Torsello A.; Palmitoylethanolamide modulation of microglia activation: Characterization of mechanisms of action and implication for its neuroprotective effects. Int J Mol Sci 2021,22(6),3054","journal-title":"Int J Mol Sci"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"S87","DOI":"10.1016\/j.pain.2013.03.023","volume":"154","author":"Maione S.","year":"2013","unstructured":"Maione S.; Costa B.; Di Marzo V.; Endocannabinoids: A unique opportunity to develop multitarget analgesics. Pain 2013,154(Suppl. 1),S87-S93","journal-title":"Pain"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1124\/mol.104.006353","volume":"67","author":"Lo Verme J.","year":"2005","unstructured":"Lo Verme J.; Fu J.; Astarita G.; La Rana G.; Russo R.; Calignano A.; Piomelli D.; The nuclear receptor peroxisome proliferator-activated receptor-alpha mediates the anti-inflammatory actions of palmitoylethanolamide. Mol Pharmacol 2005,67(1),15-19","journal-title":"Mol Pharmacol"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1038\/sj.bjp.0707460","volume":"152","author":"Ryberg E.","year":"2007","unstructured":"Ryberg E.; Larsson N.; Sj\u00f6gren S.; Hjorth S.; Hermansson N-O.; Leonova J.; Elebring T.; Nilsson K.; Drmota T.; Greasley P.J.; The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol 2007,152(7),1092-1101","journal-title":"Br J Pharmacol"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/S0014-5793(01)02934-9","volume":"506","author":"De Petrocellis L.","year":"2001","unstructured":"De Petrocellis L.; Davis J.B.; Di Marzo V.; Palmitoylethanolamide enhances anandamide stimulation of human vanilloid VR1 receptors. FEBS Lett 2001,506(3),253-256","journal-title":"FEBS Lett"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1042\/bj3580249","volume":"358","author":"Di M.A.R.Z.O.","year":"2001","unstructured":"Di M.A.R.Z.O.; V.; Melck, D.; Orlando, P.; Bisogno, T.; Zagoory, O.; Bifulco, M.; Vogel, Z.; de Petrocellis, L. Palmitoylethanolamide inhibits the expression of fatty acid amide hydrolase and enhances the anti-proliferative effect of anandamide in human breast cancer cells. Biochem J 2001,358(1),249-255","journal-title":"Biochem J"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1038\/bjp.2008.324","volume":"155","author":"Ho W-S.V.","year":"2008","unstructured":"Ho W-S.V.; Barrett D.A.; Randall M.D.; \u2018Entourage\u2019 effects of N -palmitoylethanolamide and N -oleoylethanolamide on vasorelaxation to anandamide occur through TRPV1 receptors. Br J Pharmacol 2008,155(6),837-846","journal-title":"Br J Pharmacol"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1111\/bph.13084","volume":"173","author":"Petrosino S.","year":"2016","unstructured":"Petrosino S.; Schiano Moriello A.; Cerrato S.; Fusco M.; Puigdemont A.; De Petrocellis L.; Di Marzo V.; The anti-inflammatory mediator palmitoylethanolamide enhances the levels of 2-arachidonoyl-glycerol and potentiates its actions at TRPV1 cation channels. Br J Pharmacol 2016,173(7),1154-1162","journal-title":"Br J Pharmacol"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"3193","DOI":"10.1098\/rstb.2012.0313","volume":"367","author":"Skaper S.D.","year":"2012","unstructured":"Skaper S.D.; Di Marzo V.; Endocannabinoids in nervous system health and disease: The big picture in a nutshell. Philos Trans R Soc Lond B Biol Sci 2012,367(1607),3193-3200","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"284","DOI":"10.3389\/fnmol.2017.00284","volume":"10","author":"Deuis J.R.","year":"2017","unstructured":"Deuis J.R.; Dvorakova L.S.; Vetter I.; Methods used to evaluate pain behaviors in rodents. Front Mol Neurosci 2017,10,284","journal-title":"Front Mol Neurosci"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1111\/bph.12633","volume":"172","author":"Henderson G.","year":"2015","unstructured":"Henderson G.; The \u03bc-opioid receptor: An electrophysiologist\u2019s perspective from the sharp end. Br J Pharmacol 2015,172(2),260-267","journal-title":"Br J Pharmacol"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"31","DOI":"10.5582\/ddt.2012.v6.1.31","volume":"6","author":"Iwai S.","year":"2012","unstructured":"Iwai S.; Kiguchi N.; Kobayashi Y.; Fukazawa Y.; Saika F.; Ueno K.; Yamamoto C.; Kishioka S.; Inhibition of morphine tolerance is mediated by painful stimuli via central mechanisms. Drug Discov Ther 2012,6(1),31-37","journal-title":"Drug Discov Ther"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1172\/JCI70236","volume":"124","author":"Xu J.T.","year":"2014","unstructured":"Xu J.T.; Zhao J.Y.; Zhao X.; Ligons D.; Tiwari V.; Atianjoh F.E.; Lee C.Y.; Liang L.; Zang W.; Njoku D.; Raja S.N.; Yaster M.; Tao Y.X.; Opioid receptor\u2013triggered spinal mTORC1 activation contributes to morphine tolerance and hyperalgesia. J Clin Invest 2014,124(2),592-603","journal-title":"J Clin Invest"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1124\/pr.112.005942","volume":"65","author":"Williams J.T.","year":"2013","unstructured":"Williams J.T.; Ingram S.L.; Henderson G.; Chavkin C.; von Zastrow M.; Schulz S.; Koch T.; Evans C.J.; Christie M.J.; Regulation of \u03bc-opioid receptors: desensitization, phosphorylation, internalization, and tolerance. Pharmacol Rev 2013,65(1),223-254","journal-title":"Pharmacol Rev"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.cobeha.2016.12.003","volume":"13","author":"Cahill C.M.","year":"2017","unstructured":"Cahill C.M.; Taylor A.M.W.; Neuroinflammation\u2014a co-occurring phenomenon linking chronic pain and opioid dependence. Curr Opin Behav Sci 2017,13,171-177","journal-title":"Curr Opin Behav Sci"},{"key":"ref=49","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1177\/1073858403259950","volume":"10","author":"DeLeo J.A.","year":"2004","unstructured":"DeLeo J.A.; Tanga F.Y.; Tawfik V.L.; Neuroimmune activation and neuroinflammation in chronic pain and opioid tolerance\/hyperalgesia. Neuroscientist 2004,10,40-52","journal-title":"Neuroscientist"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1126\/science.aag2590","volume":"353","author":"Ransohoff R.M.","year":"2016","unstructured":"Ransohoff R.M.; How neuroinflammation contributes to neurodegeneration. Science 2016,353(6301),777-783","journal-title":"Science"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1038\/nm.4397","volume":"23","author":"Salter M.W.","year":"2017","unstructured":"Salter M.W.; Stevens B.; Microglia emerge as central players in brain disease. Nat Med 2017,23(9),1018-1027","journal-title":"Nat Med"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1038\/nn.3295","volume":"16","author":"Ferrini F.","year":"2013","unstructured":"Ferrini F.; Trang T.; Mattioli T.A.M.; Laffray S.; Del\u2019Guidice T.; Lorenzo L.E.; Castonguay A.; Doyon N.; Zhang W.; Godin A.G.; Mohr D.; Beggs S.; Vandal K.; Beaulieu J.M.; Cahill C.M.; Salter M.W.; De Koninck Y.; Morphine hyperalgesia gated through microglia-mediated disruption of neuronal Cl\u2212 homeostasis. Nat Neurosci 2013,16(2),183-192","journal-title":"Nat Neurosci"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.bbi.2013.01.088","volume":"32","author":"Vacca V.","year":"2013","unstructured":"Vacca V.; Marinelli S.; Luvisetto S.; Pavone F.; Botulinum toxin A increases analgesic effects of morphine, counters development of morphine tolerance and modulates glia activation and \u03bc opioid receptor expression in neuropathic mice. Brain Behav Immun 2013,32,40-50","journal-title":"Brain Behav Immun"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"300","DOI":"10.3389\/fimmu.2020.00300","volume":"11","author":"Machelska H.","year":"2020","unstructured":"Machelska H.; Celik M.\u00d6.; Opioid receptors in immune and glial cells\u2014implications for pain control. Front Immunol 2020,11,300","journal-title":"Front Immunol"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1100\/tsw.2007.230","volume":"7","author":"Hutchinson M.R.","year":"2007","unstructured":"Hutchinson M.R.; Bland S.T.; Johnson K.W.; Rice K.C.; Maier S.F.; Watkins L.R.; Opioid-induced glial activation: Mechanisms of activation and implications for opioid analgesia, dependence, and reward. Sci World J 2007,7,98-111","journal-title":"Sci World J"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"6325","DOI":"10.1073\/pnas.1200130109","volume":"109","author":"Wang X.","year":"2012","unstructured":"Wang X.; Loram L.C.; Ramos K.; de Jesus A.J.; Thomas J.; Cheng K.; Reddy A.; Somogyi A.A.; Hutchinson M.R.; Watkins L.R.; Yin H.; Morphine activates neuroinflammation in a manner parallel to endotoxin. Proc Natl Acad Sci USA 2012,109(16),6325-6330","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.peptides.2019.01.003","volume":"115","author":"Eidson L.N.","year":"2019","unstructured":"Eidson L.N.; Murphy A.Z.; Inflammatory mediators of opioid tolerance: Implications for dependency and addiction. Peptides 2019,115,51-58","journal-title":"Peptides"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/j.neuroscience.2013.05.018","volume":"247","author":"Berta T.","year":"2013","unstructured":"Berta T.; Liu Y.C.; Xu Z.Z.; Ji R.R.; Tissue plasminogen activator contributes to morphine tolerance and induces mechanical allodynia via astrocytic IL-1\u03b2 and ERK signaling in the spinal cord of mice. Neuroscience 2013,247,376-385","journal-title":"Neuroscience"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2013\/753656","volume":"2013","author":"Taves S.","year":"2013","unstructured":"Taves S.; Berta T.; Chen G.; Ji R.R.; Microglia and spinal cord synaptic plasticity in persistent pain. Neural Plast 2013,2013,1-10","journal-title":"Neural Plast"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.3389\/fimmu.2020.01416","volume":"11","author":"Matejuk A.","year":"2020","unstructured":"Matejuk A.; Ransohoff R.M.; Crosstalk between astrocytes and microglia: An overview. Front Immunol 2020,11,1416","journal-title":"Front Immunol"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/0014-2999(96)00015-5","volume":"300","author":"Mazzari S.","year":"1996","unstructured":"Mazzari S.; Canella R.; Petrelli L.; Marcolongo G.; Leon A.N.; -(2-Hydroxyethyl)hexadecanamide is orally active in reducing edema formation and inflammatory hyperalgesia by down-modulating mast cell activation. Eur J Pharmacol 1996,300(3),227-236","journal-title":"Eur J Pharmacol"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.pain.2008.06.003","volume":"139","author":"Costa B.","year":"2008","unstructured":"Costa B.; Comelli F.; Bettoni I.; Colleoni M.; Giagnoni G.; The endogenous fatty acid amide, palmitoylethanolamide, has anti-allodynic and anti-hyperalgesic effects in a murine model of neuropathic pain: involvement of CB1, TRPV1 and PPAR\u03b3 receptors and neurotrophic factors. Pain 2008,139(3),541-550","journal-title":"Pain"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1097\/j.pain.0000000000000220","volume":"157","author":"Iuvone T.","year":"2016","unstructured":"Iuvone T.; Affaitati G.; De Filippis D.; Lopopolo M.; Grassia G.; Lapenna D.; Negro L.; Costantini R.; Vaia M.; Cipollone F.; Ialenti A.; Giamberardino M.A.; Ultramicronized palmitoylethanolamide reduces viscerovisceral hyperalgesia in a rat model of endometriosis plus ureteral calculosis. Pain 2016,157(1),80-91","journal-title":"Pain"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1007\/s12035-013-8487-6","volume":"48","author":"Skaper S.D.","year":"2013","unstructured":"Skaper S.D.; Facci L.; Giusti P.; Glia and mast cells as targets for palmitoylethanolamide, an anti-inflammatory and neuroprotective lipid mediator. Mol Neurobiol 2013,48(2),340-352","journal-title":"Mol Neurobiol"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1186\/s12974-019-1671-5","volume":"16","author":"Petrosino S.","year":"2019","unstructured":"Petrosino S.; Schiano Moriello A.; Verde R.; Allar\u00e0 M.; Imperatore R.; Ligresti A.; Mahmoud A.M.; Peritore A.F.; Iannotti F.A.; Di Marzo V.; Palmitoylethanolamide counteracts substance P-induced mast cell activation in vitro by stimulating diacylglycerol lipase activity. J Neuroinflammation 2019,16(1),274","journal-title":"J Neuroinflammation"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/S0304-3959(03)00261-6","volume":"105","author":"Zuo Y.","year":"2003","unstructured":"Zuo Y.; Perkins N.M.; Tracey D.J.; Geczy C.L.; Inflammation and hyperalgesia induced by nerve injury in the rat: A key role of mast cells. Pain 2003,105(3),467-479","journal-title":"Pain"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1159\/000125048","volume":"14","author":"Smith F.M.","year":"2007","unstructured":"Smith F.M.; Haskelberg H.; Tracey D.J.; Moalem-Taylor G.; Role of histamine H3 and H4 receptors in mechanical hyperalgesia following peripheral nerve injury. Neuroimmunomodulation 2007,14(6),317-325","journal-title":"Neuroimmunomodulation"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1111\/bph.14696","volume":"177","author":"Obara I.","year":"2020","unstructured":"Obara I.; Telezhkin V.; Alrashdi I.; Chazot P.L.; Histamine, histamine receptors, and neuropathic pain relief. Br J Pharmacol 2020,177(3),580-599","journal-title":"Br J Pharmacol"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1111\/vde.12456","volume":"28","author":"Abramo F.","year":"2017","unstructured":"Abramo F.; Lazzarini G.; Pirone A.; Lenzi C.; Albertini S.; della Valle M.F.; Schievano C.; Vannozzi I.; Miragliotta V.; Ultramicronized palmitoylethanolamide counteracts the effects of compound 48\/80 in a canine skin organ culture model. Vet Dermatol 2017,28(5),456-e104","journal-title":"Vet Dermatol"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.vetimm.2009.06.011","volume":"133","author":"Cerrato S.","year":"2010","unstructured":"Cerrato S.; Brazis P.; della Valle M.F.; Miolo A.; Puigdemont A.; Effects of palmitoylethanolamide on immunologically induced histamine, PGD2 and TNF\u03b1 release from canine skin mast cells. Vet Immunol Immunopathol 2010,133(1),9-15","journal-title":"Vet Immunol Immunopathol"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"326","DOI":"10.2174\/1871527318666190227205359","volume":"18","author":"Schweiger V.","year":"2019","unstructured":"Schweiger V.; Martini A.; Bellamoli P.; Donadello K.; Schievano C.; Balzo G.D.; Sarzi-Puttini P.; Parolini M.; Polati E.; Ultramicronized palmitoylethanolamide (um-PEA) as add-on treatment in fibromyalgia syndrome (FMS): Retrospective observational study on 407 patients. CNS Neurol Disord Drug Targets 2019,18(4),326-333","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2020\/3938640","volume":"2020","author":"Papetti L.","year":"2020","unstructured":"Papetti L.; Sforza G.; Tullo G.; Alaimo di Loro P.; Moavero R.; Ursitti F.; Ferilli M.A.N.; Tarantino S.; Vigevano F.; Valeriani M.; Tolerability of palmitoylethanolamide in a pediatric population suffering from migraine: A pilot study. Pain Res Manag 2020,2020,1-7","journal-title":"Pain Res Manag"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"491","DOI":"10.2174\/1871527318666190703110036","volume":"18","author":"Cruccu G.","year":"2019","unstructured":"Cruccu G.; Stefano G.D.; Marchettini P.; Truini A.; Micronized palmitoylethanolamide: A post hoc analysis of a controlled study in patients with low back pain - sciatica. CNS Neurol Disord Drug Targets 2019,18(6),491-495","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s40122-019-00140-9","volume":"9","author":"Scaturro D.","year":"2020","unstructured":"Scaturro D.; Asaro C.; Lauricella L.; Tomasello S.; Varrassi G.; Letizia Mauro G.; Combination of rehabilitative therapy with ultramicronized palmitoylethanolamide for chronic low back pain: An observational study. Pain Ther 2020,9(1),319-326","journal-title":"Pain Ther"}],"container-title":["Current Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1570159X21666221128091453","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/211285\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1570159X21666221128091453","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T06:50:23Z","timestamp":1700635823000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/211285\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":74,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1570159x21666221128091453","relation":{},"ISSN":["1570-159X"],"issn-type":[{"value":"1570-159X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2022-09-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-11-04","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-11-05","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-20","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}